The stock has had a terrific year, but RBC analyst Paul Treiber thinks there is still money to be made on Celestica (Celestica Stock Quote, Chart, News, Analysts, Financials NYSE:CLS).
In a research update to clients July 25, Treiber maintained his “Buy” rating and price target of $65.00 on CLS.
On July 24, CLS reported its Q2, 2024 results. The company posted EPS of $0.83 on revenue of $2.39-billion, a topline that was up 23% year-over-year.
“We are pleased to deliver another quarter of very strong performance in Q2 2024, with revenue up 23% year-to-year and non-IFRS adjusted EPS* up 65% year-to-year”. CEO Rob Mionis said. “With our strong performance in the first half of the year and favorable demand dynamics continuing, we are pleased to raise our full year 2024 outlook. We anticipate achieving revenue of $9.45 billion and non-IFRS adjusted EPS* of $3.62 in 2024, which, if achieved, would represent 19% and 49% growth, respectively, compared to 2023. We continue to stay focused on solid execution for our customers, and delivering on our strategic priorities and financial targets.”
Following a sizeable acquisition, Paradigm Capital analyst Daniel Rosenberg has raised his price target on VitalHub (VitalHub Stock Quote, Chart,… [Read More]
Following a recent contract win, Ventum Capital markets analyst Rob Goff has raised his price target on Volatus Aerospace (Volatus… [Read More]
Canada’s labour market has softened sharply since the start of the year, with the unemployment rate reaching 7% in May,… [Read More]
Count RBC Capital Markets analyst Ken Herbert among the believers in MDA (MDA Stock Quote, Chart, News, Analysts, Financials TSX:MDA).… [Read More]
Roth Capital Markets analyst Suji Desilva said in a July 3 report that Netlist (Netlist Stock Quote, Chart, News, Analysts,… [Read More]
Research Capital analyst Andre Uddin is recommending Theratechnologies (Theratechnologies Stock Quote, Chart, News, Analysts, Financials NASDAQ:THTX) shareholders tender their shares… [Read More]